Private Asset Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Private Asset Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-63,975	Closed	-$1.92M	–	152
2016 Q3	$1.92M	Buy	63,975 +57,600	+904%	+$1.79M	0.32%	64
2016 Q2	$245K	Sell	6,375 -600	-9%	-$24.9K	0.04%	127
2016 Q1	$266K	Buy	6,975 +600	+9%	+$20.9K	0.05%	119
2015 Q4	$280K	Buy	6,375 +1,225	+24%	+$60.8K	0.05%	116
2015 Q3	$210K	Buy	+5,150	New	+$226K	0.04%	125

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Private Asset Management's JUNO Position: Q4 2016 in Review

Private Asset Management sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2016, closing a stake of 63,975 shares — an estimated $1.92M sold.

Private Asset Management first reported a position in JUNO in Q3 2015 and held it in 5 quarters. The position peaked at $1.92M in Q3 2016. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

Private Asset Management reported no remaining Juno Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
Private Asset Management sold 63,975 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $1.92M.
Private Asset Management first reported a position in Juno Therapeutics, Inc. in Q3 2015 and held it in 5 quarters.
Private Asset Management's Juno Therapeutics, Inc. position peaked at $1.92M in Q3 2016.
159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on Private Asset Management's 13F filing for Q4 2016, filed 4 Jan 2017.